Discover how researchers are using eGFR cutoffs to predict chronic kidney disease in children with lupus nephritis. Exciting findings ahead!
Lupus nephritis, a challenging condition affecting many individuals, poses significant risks of developing chronic kidney disease (CKD). Recent studies have delved into the predictive capabilities of glomerular filtration rates (eGFR) in determining the progression to CKD in lupus nephritis patients. One groundbreaking discovery revealed that an eGFR cutoff of 75 mL/min/1.73 m2 after a year of treatment could accurately predict the onset of CKD. This advancement offers hope for early intervention and improved management of kidney complications in lupus patients.
Furthermore, researchers have embarked on a decade-long journey studying children with lupus nephritis to unveil predictors of kidney disease and failure, including end-stage kidney disease (ESKD). By closely monitoring these young patients, investigators have identified key factors that can signal the development of CKD and serve as early warning signs for progression to ESKD. These findings are crucial in enhancing the long-term care and outcomes for children battling lupus nephritis.
In the realm of lupus research, the exploration of eGFR cutoffs as a predictive tool for CKD and the identification of predictors for ESKD in children with lupus nephritis mark significant strides in understanding and managing kidney complications in lupus patients. By leveraging these insights, healthcare professionals can proactively intervene and tailor treatment plans to safeguard the kidney health of individuals with lupus nephritis.
An eGFR cutoff of 75 mL/min/1.73 m2 after 1 year of treatment was predictive of progression to chronic kidney disease among patients with lupus nephritis.
Investigators followed children with lupus nephritis for a decade or more to identify initial predictors of kidney disease and failure (ESKD).
Celebrities with lupus, including Selena Gomez and Nick Cannon, share their experiences in order to raise awareness about the chronic condition.
Despite prior setbacks, Lilly executives said they're pressing ahead with new research in lupus at a time when other companies are taking to cell therapy โฆ